Excellamol has developed a next-generation platform of Self-Depot™ OncoPDC therapeutics engineered to achieve sustained local retention, prolonged tumor exposure, and minimal systemic leakage in difficult-to-penetrate solid tumors.

The platform integrates self-assembling polypeptides, tumor-targeting ligands, and highly potent anticancer payloads to enable prolonged tumor retention, sustained intracranial exposure, and reduced systemic leakage following local administration.

Excellamol has received five U.S. FDA Orphan Drug Designations and successfully completed FDA regulatory interactions supporting IND-enabling development and first-in-human clinical planning.

The Company is currently advancing GLP toxicology, pharmacokinetic, and CMC activities in support of the clinical development of novel therapies for malignant glioma and pancreatic cancer, both of which are hard-to-treat cancers associated with high mortality.